The selective 5-HT1F receptor agonist lasmiditan inhibits trigeminal nociceptive processing: Implications for migraine and cluster headache.

Marta Vila-PueyoKeith PagePaul R MurdockHoward J LoraineAmanda J WoodrooffeKirk W JohnsonPeter J GoadsbyPhilip Robert Holland
Published in: British journal of pharmacology (2021)
Our data suggest that lasmiditan acts, at least in part, as an anti-migraine agent by reducing trigeminovascular activation. Furthermore, our results highlight a clear action for lasmiditan in a preclinical model of cluster headache. Given the proven translational efficacy of this model, our data support the potential utility of lasmiditan as a therapeutic option for the acute treatment of cluster headache attacks.